Spinogenix Reports Positive Initial Results from Phase 2a Alzheimer’s Trial of SPG302

RefinitivMenos de 1 minuto de lectura

SPINOGENIX ANNOUNCES POSITIVE FIRST COHORT RESULTS FROM PHASE 2A TRIAL EVALUATING SPG302 FOR ALZHEIMER'S DISEASE

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Inicie sesión o cree una cuenta gratuita y permanente para leer esta noticia